Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Changes in Liver Function After Stereotactic Body Radiation Therapy Measured by PET/CT

The recruitment status of this study is unknown because the information has not been verified recently.
Verified March 2012 by University of Aarhus.
Recruitment status was  Recruiting
Sponsor:
Collaborator:
Danish Cancer Society
Information provided by (Responsible Party):
University of Aarhus
ClinicalTrials.gov Identifier:
NCT01213758
First received: October 1, 2010
Last updated: March 21, 2012
Last verified: March 2012

October 1, 2010
March 21, 2012
June 2010
January 2013   (final data collection date for primary outcome measure)
Uptake of FDGal [ Time Frame: Before, 1 month and 3 months after stereotactic radiotherapy ] [ Designated as safety issue: No ]
Volumetric uptake of FDGal can be measured is measured by PET/CT
Same as current
Complete list of historical versions of study NCT01213758 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Changes in Liver Function After Stereotactic Body Radiation Therapy Measured by PET/CT
Radiation Induced Change of Liver Function Measured by Uptake of the Galactose Analogue FDGal and PET/CT

Patients treated with stereotactic radiotherapy for liver tumors undergo PET/CT using the galactose analogue 18-F-deoxy-galactose (FDGal) before and after radiotherapy. This technique provides volumetric mapping of liver function and it allows quantisation of liver function. The method may be used for selection of patients for stereotactic radiotherapy of liver tumors, for determination of radiation induced liver dysfunction and may be included into the treatment planning process of stereotactic radiotherapy.

Not Provided
Interventional
Not Provided
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Diagnostic
  • Hepatocellular Carcinoma
  • Cholangiocarcinoma
  • Metastases
  • Stereotactic Body Radiotherapy
Other: Measuring liver function by PET/CT
Measuring liver function by use of FDGal and PET/CT before, 1 month and 3 months after stereotactic radiotherapy for liver tumors
No Intervention: Liver tumors
Patients where stereotactic body radiation therapy is planned for primary or metastatic liver tumors.
Intervention: Other: Measuring liver function by PET/CT
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
20
May 2013
January 2013   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • liver tumor
  • referred for stereotactic radiation therapy
  • age > 18 years

Exclusion Criteria:

  • Impaired kidney function
  • Pregnancy
Both
18 Years to 85 Years
No
Contact: Morten Høyer, MD PhD +45 89492529 hoyer@aarhus.rm.dk
Denmark
 
NCT01213758
AarhusLiverRadGal
No
University of Aarhus
University of Aarhus
Danish Cancer Society
Principal Investigator: Morten Høyer, MD PhD Aarhus University Hospital
University of Aarhus
March 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP